Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $10.8 million.

  • TScan Therapeutics' Accumulated Expenses fell 372.06% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 372.06%. This contributed to the annual value of $15.4 million for FY2024, which is 4380.37% up from last year.
  • Latest data reveals that TScan Therapeutics reported Accumulated Expenses of $10.8 million as of Q3 2025, which was down 372.06% from $12.8 million recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' Accumulated Expenses registered a high of $15.4 million during Q4 2024, and its lowest value of $3.0 million during Q1 2022.
  • In the last 5 years, TScan Therapeutics' Accumulated Expenses had a median value of $8.5 million in 2023 and averaged $8.3 million.
  • Per our database at Business Quant, TScan Therapeutics' Accumulated Expenses soared by 16130.71% in 2021 and then tumbled by 372.06% in 2025.
  • Over the past 5 years, TScan Therapeutics' Accumulated Expenses (Quarter) stood at $6.5 million in 2021, then grew by 4.93% to $6.8 million in 2022, then surged by 56.71% to $10.7 million in 2023, then soared by 43.8% to $15.4 million in 2024, then crashed by 30.14% to $10.8 million in 2025.
  • Its Accumulated Expenses was $10.8 million in Q3 2025, compared to $12.8 million in Q2 2025 and $9.6 million in Q1 2025.